Avidity Biosciences Inc (RNA) Stock Price, Quote & News

Company Profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac disea...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 876 0700

Website: atriumtherapeutics.com

Address:

10578 Science Center Drive, Suite 125, San Diego, United States

d_risk Jun. 2 at 1:15 PM

$RNA - Avidity Biosciences Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +268.9% above peer average (43,350 vs 11,751 across 654 peers). RNA’s updated 10-Q sharpens early-stage and financing risks: newly public, preclinical-only, loss-making, with an unproven cardiac RNA platform, heavy reliance on Avidity and big-pharma partners, growing regulatory/tax burdens, and fresh warnings on internal controls, market volatility, and potential shareholder litigation. #Biotechnology #EarlyStageRisk #PartnershipDependence #RegulatoryChallenges #MarketVolatility 🟢 Added 🟠 Removed https://d-risk.ai/RNA/10-Q/2026-05-14

0 · Reply

SuperGreenToday May. 21 at 10:55 PM

$RNA Share Price: $13.02 Contract Selected: Jan 15, 2027 $20 Calls Buy Zone: $41.65 – $51.45 Target Zone: $68.35 – $83.54 Potential Upside: 55% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Vandelay_Industries_Inc May. 15 at 4:35 PM

$RNA ER is fine. No major surprises. Cash burn is reasonable. Stock trades at a 25% discount to cash on balance sheet. Looking forward to 1-2 IND filings in 2H26. Don't see why it shouldn't move higher towards $17+ near term to align with 1x cash.

0 · Reply

focafoca99 May. 14 at 9:18 PM

$RNA launched its Q1 2026 earnings release, reporting results for the quarter ended March 31, 2026.

0 · Reply

BillionerOfKing Apr. 30 at 2:22 PM

$RNA Current Stock Price: $12.96 Contracts to trade: $33.0 RNA Jun 18 2026 Call Entry: $19.50 Exit: $37.65 ROI: 93% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Fingerlickengood Apr. 29 at 1:18 PM

$CDXS $RNA $MRK $IONS https://www.globenewswire.com/news-release/2026/04/29/3283814/24825/en/Codexis-to-share-RNA-manufacturing-advances-at-TIDES-USA.html

2 · Reply

Fingerlickengood Apr. 26 at 3:26 PM

$CDXS $RNA $BMY https://acsgcipr.org/sustainable-manufacturing-of-bms-986278-leveraging-an-ered-kred-biocatalytic-cascade/

1 · Reply

focafoca99 Apr. 21 at 6:55 AM

$RNA granted inducement awards covering 101,250 stock options and 50,625 restricted stock units to seven new non-executive hires.

0 · Reply

LiveCommander Apr. 19 at 2:25 PM

Squeeze Wachlist for Mon Apr 19: - $TRAX.X | First Tracks Biotherapeutics | Spinoff - New Listing - $ANAB | AnaptysBio | First trading post distribution Both have potential to replicate the x4 of $RNA on its Feb 27 debut. Volatility on large caps is a gift!

1 · Reply

Fingerlickengood Mar. 20 at 3:49 PM

$CDXS $NVS $RNA And lines up nicely with an 'unnamed company' in their latest PR . "This agreement allows Codexis to supply siRNA material to support its partner’s preclinical program targeting a cardiovascular indication. Successfully delivering 50 grams marks an inflection point—more than tenfold typical research volumes—signaling Codexis’s capability to meet more demanding supply needs as RNA therapies expand into more prevalent diseases." Just saying ;) https://marketchameleon.com/articles/b/2026/3/5/codexis-agreement-50g-sirna-eco-synthesis-platform-expansion

1 · Reply